Personalis, Inc.’s Post

📌 healthbook ASCO 2023 Highlights Now Released! Explore significant findings from this year's symposium: 🔹 BREAST CANCER: Investigate the consistent treatment benefits across age subgroups in HR-Positive, HER2-Negative early-stage breast cancer. 🔹 LUNG CANCER: Learn more about the intracranial efficacy of a KRAS inhibitor specific to lung cancer scenarios. 🔹 HEMATOLOGIC MALIGNANCIES: Unveil the evolving treatment paradigm for refractory or early-relapsed LBCL. https://lnkd.in/ecji8uYR #ASCO2023 #healthbookHighlights #BreastCancerResearch #LungCancerInsights #HematologicMalignancies

Colon Cancer to Outpace Breast Cancer by 2040 as Leader in Cancer Cases | Dr. Anton Bilchik discusses the rise of colorectal cancer incidents; Recent data reveals an alarming trend. “What we are seeing in colon cancer is unprecedented because colon cancer has become a disease of younger people…We now have FIT tests.” – Anton Bilchik, MD, Ph.D., FACS Learn more on our blog and listen to Dr. Anton Bilchik provide perspective and likely reasoning for colon cancer occurrence earlier in life: https://lnkd.in/g7TSzgur Dr. Anton Bilchik: https://lnkd.in/gG7Ke2qJ #coloncancerawareness #colorectalcancerawareness #saintjohnscancerinstitute #cancerprevention

Our own Katyayani Papatla, MD, and Peter Dottino, MD, recently presented a CME series on #GynecologicOncology Treatment and Care. The discussion focused on the Diagnosis and Treatment of #EndometrialCancer, Understanding Adnexal Masses #CervicalCancer Screening, and Cervical Cancer Screening. Catch the video to learn more about all of these topics. Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital

In 2023, an estimated 288,300 men in the United States will be diagnosed with prostate cancer - and, worldwide, an estimated 1,414,259 people were diagnosed with prostate cancer in 2020 according to Cancer.net. The current guidelines in America over-diagnose, under-diagnose and miss an astonishing 30-40% of the cancer. And many treatment options, such as radiation, pose a 20-30% recurrence rate. Busch Center is proud to be #1 in North America and #2 in the World for performing TULSA (Transurethral Ultrasound Ablation) Pro Treatment. This is an effective treatment option for prostate cancer or BPH (benign prostatic hypertrophy) with no incision or radiation and minimal side effects. Learn more at https://lnkd.in/gmyAX47t. Help us spread the word for #ProstateCancerAwarenessMonth by clicking the share button.

Although there's no straightforward remedy for curing cancer, one fact stands clear: early detection significantly improves our chances of defeating it. In the case of colorectal cancer, for instance, early diagnosis leads to a 90% survival rate. While effective screening methods like colonoscopies for colorectal cancer and mammograms for breast cancer are available and proven to save lives, the persistently high cancer mortality rates indicate that not everyone receives timely screenings. Learn more about the importance of early detection on our website: https://lnkd.in/gBGQr3RH #earlycancerdetection #liquidbiopsy #cancerscreening #cancer

Although there's no straightforward remedy for curing cancer, one fact stands clear: early detection significantly improves our chances of defeating it. In the case of colorectal cancer, for instance, early diagnosis leads to a 90% survival rate. While effective screening methods like colonoscopies for colorectal cancer and mammograms for breast cancer are available and proven to save lives, the persistently high cancer mortality rates indicate that not everyone receives timely screenings. Learn more about the importance of early detection on our website: https://lnkd.in/gBGQr3RH #earlycancerdetection #liquidbiopsy #cancerscreening #cancer

Colorectal cancer remains a major health challenge, being the fourth most common cancer and the fourth leading cause of cancer-related deaths in the United States. Thank you Freenome from bringing such an important health matter to focus. This further underscores the importance of regular screenings and awareness of early symptoms, as timely diagnosis can significantly improve the prognosis for those affected by this disease. The significance of early detection in colorectal cancer cannot be overstated, as it dramatically influences survival rates. According to the American Cancer Society, the 5-year relative survival rates for colorectal cancer vary significantly based on the stage at diagnosis. For localized colorectal cancer, where the cancer has not spread outside the colon or rectum, the 5-year relative survival rate is about 91% for colon cancer and 90% for rectal cancer. However, when the cancer has spread to distant parts of the body, the survival rates drop to 13% for colon cancer and 18% for rectal cancer. These statistics highlight the critical importance of early detection in improving outcomes for colorectal cancer patients. #colorectalcancer #bitoech #earlydetection

Discover the basics and the latest in cancer immunotherapy from top experts, including CRI Scientific Advisory Council Associate Director and Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, Dr. Jedd Wolchok, during the Cancer Research Institute’s virtual Patient Immunotherapy Summit. Watch the program on demand, at no cost, today: https://bit.ly/3Nhmefn #Immunotherapy #CancerResearch #CRISummit #PatientSummit

The 2023 Cancer Statistics from the American Cancer Society highlight that #BreastCancer is still the most common cancer diagnosed among women. Even though there have been significant strides in early detection and treatment, managing metastatic tumors remains a complex issue. October marks #BreastCancerAwarenessMonth. Our aim is to emphasize the importance of continued research and to motivate the creation of innovative breast cancer treatments by showcasing the latest developments in its therapeutics. #WomensHealth #MoreThanBCAM #BreastCancerSupport

The most important specific treatment for lobular cancer is endocrine therapy. That’s its backbone treatment to prevent relapse. The vast majority of classic lobular cancers are estrogen dependent and the biggest mistake in treatment that I see repeatedly is stopping endocrine therapy prematurely in the adjuvant setting allowing for relapse. Understanding lobular biology is key to prevent unnecessary relapses. Any patient with a diagnosis of lobular carcinoma on adjuvant endocrine therapy whose oncologist plans to stop treatment, should seek an expert second opinion before they do. That is my practical advice for all patients with lobular cancer. #lobularcarcinoma #ILC #endocrinetherapy #tamoxifen